Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $9.62 and traded as low as $8.97. Astellas Pharma shares last traded at $9.23, with a volume of 206,985 shares trading hands.
Astellas Pharma Price Performance
The company has a market capitalization of $16.97 billion, a P/E ratio of -42.63 and a beta of 0.27. The company's 50-day moving average price is $9.59 and its two-hundred day moving average price is $9.87. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.04 and a quick ratio of 0.80.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.12. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.02 billion. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. As a group, sell-side analysts expect that Astellas Pharma Inc. will post 0.42 EPS for the current year.
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Read More
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
